ArticleAutism research : official journal of the International Society for Autism Research2026
Characterization of Anticholinergic Medication Use and Its Associations With Everyday Memory Problems and Cognitive Decline in Autistic Adults With Higher Support Needs.
Article in Autism research : official journal of the International Society for Autism Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Among older adults in the general population, medications with anticholinergic (AC) effects are associated with declines in cognitive functioning and with dementia and Alzheimer's disease. Autistic people have high rates of co-occurring medical conditions and polypharmacy across the lifespan; thus, they may be at particularly high risk of exposure to AC medications and their negative impacts on cognitive functioning, including earlier in adulthood. Consistent with this, a single study has shown AC medication use is prevalent among autistic adults without co-occurring intellectual disability and is associated with self-reported concurrent memory problems and declines in cognition. No study has examined AC medications and their associations with cognition among autistic adults with higher support needs. We therefore characterized AC medication use and its associations with caregiver-rated memory problems and changes in cognition and behavior that have been linked with cognitive decline. Caregivers of autistic adults (18-68 years; Mean ~31 years) recruited via Simons Powering Autism Research's (SPARK) Research Match service reported medication use (N = 512), memory complaints (N = 467), and a screener that probes behavior/cognitive changes (N = 466) that are associated with cognitive decline among persons with an intellectual disability. The majority (66.41%) of autistic adults were taking at least one AC medication and 31% were taking clinically-meaningful levels of these medications. After controlling for age and birth sex, greater potency of AC medications was associated with both caregiver-reported memory challenges and behavioral/cognitive changes associated with cognitive decline. Understanding AC medication use and its potential impacts on cognition among autistic adults with higher support needs is crucial.
Indexed as
Identifiers
42592704What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.